NCCN eBulletin - NCCN Updates: Guidelines, Drugs & Biologics, Order Templates

The NCCN Guidelines Panel for Kidney Cancer has added pazopanib as a first-line therapy option for those with predominant clear cell histology (category 1 designation) and for those with non clear cell histology (category 3 designation). In addition, pazopanib has been incorporated into the options for subsequent therapy for those with predominant clear cell histology following cytokine therapy (category 1 designation) and following other tyrosine kinase inhibitors (category 3 designation).

For the complete updated version of the NCCN Clinical Practice Guidelines in Oncology™, the NCCN Drugs & Biologics Compendium™, and the NCCN Chemotherapy Order Templates™ please visit NCCN.org.

National Comprehensive Cancer Network

About NCCN

NCCN Updates: Guidelines, Drugs & Biologics, Order Templates

The NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer Have Been Updated to Incorporate the Recently Approved Therapy Pazopanib as a Treatment Option for Patients with Advanced Renal Cell Carcinoma.